mHSPCde novo mHSPCmetastatic hormone-sensitive prostate cancer (mHSPC)docetaxelabirateronedarolutamideARASENSenzalutamideapalutamidePEACE-1+4 more
…veness of triplet therapies versus doublet therapies in de novo mHSPC, both overall and in high and low tumour burden subgroups (CHAA…